With the continued popularity of the high-throughput sequencing (NGS) market, non-invasive prenatal screening (NIPT) and tumor genetic testing have become the two most important application scenarios. According to relevant market analysis data, only NIPT, the domestic market size in 2020 is expected to reach 9.5 billion, and according to the prediction of Guosen Securities Research Institute, the potential of liquid biopsy in China within 5 to 10 years is about 20 billion yuan.
Less than two years after its establishment, Shunyuan Gene has been “opened up†in four major areas: tumor gene detection, NIPT, reproductive health, and infection detection. In August, Shunyuan Gene announced the completion of a $20 million Series A financing jointly invested by Lilly Asia Fund Leadership, Songhe Capital and Chende Capital.
Professor Gao Yuan, co-founder and chairman of Suiyuan Gene, told the author that the imagination of Suiyuan is not limited to this. In the application of high-throughput sequencing, they have carried out a more comprehensive layout. One of the signals is that co-founder Professor Zhang Wei has just published a research paper on the use of single-cell sequencing to study brain genomes in Science.
.jpg)
Seize the mainstream market, and make good technical first move
The co-founder and chairman of Suiyuan Gene is Professor Gao Yuan of Johns Hopkins University. Another co-founder and scientific consultant is Professor Zhang Wei of the University of California, San Diego. Based on the research accumulation of these two Chinese scientists and the technical development of the entire R&D team, Shunyuan Gene has developed four products in clinical applications.
In fact, in addition to the current hot tumor gene detection and non-invasive prenatal screening market, Suiyuan gene has already laid out many areas such as reproductive health testing and infection detection. Successful financing has undoubtedly accelerated the development of technology and the layout of products.
With the completion of the A round of financing, Suiyuan Gene announced that this round of financing will contribute to the research and development and industrial transformation of Shunyuan Gene in non-invasive gene sequencing detection products for tumors and other genetic diseases. Suiyuan Gene will also use this round of financing to further expand research and development, and accelerate the launch of new products related to cancer diagnosis and personalized treatment.
Eli Lilly Asia Fund Investment Director Xia Guofan told the author that Suiyuan is a company capable of becoming one of the leading companies in the field. The powerful team and deep technical background of Suiyuan Gene make this investment decision very easy.
Talking about the four application areas of the current layout, Zhang Jiangli, co-founder and CEO of Suiyuan Gene, expressed confidence that thanks to long-term technical accumulation, excellent R&D team, continuous innovation ability is the biggest core of Suiyuan gene. Advantage.
The first is NIPT. In August, Berry and Kang's backdoor listing once again made NIPT a fire. In this field, Suiyuan Gene has its own killer. In fact, the current mainstream technology in the domestic NIPT market is based on the collaboration between Prof. Gao Yuan, co-founder and chairman of Suiyuan Gene, and Professor Dennis Lo of the Chinese University of Hong Kong to present a famous NIPT technology breakthrough paper on PNAS. Most market giants use this technology.
In the US market, this technology is not the mainstream, and it is replaced by the second-generation NIPT technology. Compared with the first-generation technology, the second-generation technology has greatly improved in terms of sensitivity, false negative rate and cost. On the basis of this, Suiyuan Gene achieved further breakthroughs and developed 2.5 generations of technology.
Prof. Gao Yuan revealed that the advantage of the 2.5-generation NIPT technology of Suiyuan Gene is that the sensitivity and accuracy of the detection are higher; at the same time, the false negative rate is greatly reduced.
Clinical studies in the United States have shown that false negatives are closely related to mother's weight. The mother with the greater weight, the lower the proportion of fetal cfDNA, when it is low to a certain weight, it is easy to have a false negative. This is an important issue in the generation of technology. When a negative result occurs, one generation of technology can't judge whether it is really negative or because the proportion of fetal cfDNA in the whole mother is too low, resulting in false negative. The 2.5-generation NIPT technology of Suiyuan Gene solves this problem well. At the same time, the technology has also achieved a significant decline in the cost of sequencing.
Electric Eyebrow Remover,Electric Eyebrow Trimmer,Automatic Eyebrow Trimmer,Best Electric Eyebrow Trimmer
Shenzhen Jie Zhong Lian Investment Co., Ltd. , https://www.meizons.com